Home＜ News & Events

News & Events

News Events Media Attention Partner News

 

2022.10
26

TOT BIOPHARM Passed EU QP Audit with Zero Defect, indicating its Biologics Quality System Internationally Recognized

Recently, TOT BIOPHARM (Stock code: 1875.HK)gained the Compliance Inspection Report approved by the EU Qualified Person(QP). TOT BIOPHARM’s commercial antibody and antibody drug conjugates (ADC)manufacturing site in Suzhou Industrial Park headquarters hav
2022.06
08

TOT BIOPHARM CDMO | One-stop ADC Industry Platform，Empowers Drug Development

Antibody drug conjugates (ADC), known as the “magicbullet”, has been developing rapidly through continuous technologicaliterations, and especially in the past three to four years, the explosion ofADC has been achieved, with several ADC drugs approved one…
2022.06
01

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOP BIOPHARM Shares

On June 1, 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) announced that the company entered into a Share Subscription Agreement with VIVO Suzhou Fund and Centerlab. Pursuant to the agreement, Vivo Suzhou Fund and Cen
2022.03
25

TOT BIOPHARM Announces 2021 Annual Results
2022.01
11

Setting Sail! TOT BIOPHARM and Kexing Biopharm Sign Commercialization License and Cooperation Agreement on Pusintin® Overseas

11 January 2022, TOT BIOPHARM International Company Limited (TOT BIOPHARM, 1875.HK) announced the signing of an exclusive commercialization license cooperation agreement for Pusintin®’s overseas markets with Kexing BIOPHARM Co., Ltd. (Kexing Bioph